ron Oxide Magnetic esonance Imaging or Atherosclerosis herapeutic Evaluation

Abstract

ulticenter, randomized, placebo-controlled “outcome” trils with long-term follow-up of thousands of patients are urrently being used to evaluate new therapies for cardioascular disease. Owing to improvements in risk factor odifications as well as to the concomitant use of estabished treatments, such as statins, leading to a drop in linical event rates, it is projected that the number of atients enrolled in trials may need to be increased to eparate the effect of new therapies from those of established nes. Recently, the JUPITER (Justification for the Use of tatins in Primary Prevention: an Intervention Trial Evalating Rosuvastatin) study (1) showed the importance of erologic measures of inflammation. These new in-blood

Cite this paper

@inproceedings{FayadronOM, title={ron Oxide Magnetic esonance Imaging or Atherosclerosis herapeutic Evaluation}, author={Alicia Fayad and Louai Razzouk and C . Briley - Saebo} }